Low dose IL-2 supplementation could be considered as a strategy to enhance further TRegs expansion in vivo but this would require a balancing act as the cytokine could also result in the amplification of effector cell proliferation leading to exacerbation of GVHD symptoms and graft rejection. The gene discussed is IL2; the disease is graft versus host disease.